Anti-SARS-CoV-2S Antibody Levels in Healthcare Workers 10 Months after the Administration of Two BNT162b2 Vaccine Doses in View of Demographic Characteristic and Previous COVID-19 Infection

Blanka Wolszczak-Biedrzycka; Anna Bieńkowska; Joanna Ewa Zaborowska; Elwira Smolińska-Fijołek; Grzegorz Biedrzycki; Justyna Dorf

doi:10.3390/vaccines10050741

Anti-SARS-CoV-2S Antibody Levels in Healthcare Workers 10 Months after the Administration of Two BNT162b2 Vaccine Doses in View of Demographic Characteristic and Previous COVID-19 Infection

Vaccines (Basel). 2022 May 9;10(5):741. doi: 10.3390/vaccines10050741.

Authors

Blanka Wolszczak-Biedrzycka^{1

2}, Anna Bieńkowska^{1

2}, Joanna Ewa Zaborowska³, Elwira Smolińska-Fijołek⁴, Grzegorz Biedrzycki⁵, Justyna Dorf⁶

Affiliations

¹ Department of Psychology and Sociology of Health and Public Health, University of Warmia and Mazury in Olsztyn, 10-082 Olsztyn, Poland.
² The Oncology Center of the Region of Warmia and Mazury in Olsztyn, Hospital of the Ministry of the Interior and Administration, 10-228 Olsztyn, Poland.
³ District Hospital in Bartoszyce, 11-200 Bartoszyce, Poland.
⁴ Department of Physiology, Medical University in Gdańsk, 80-211 Gdańsk, Poland.
⁵ Hospital Dispensary, Regional Specialist Hospital in Olsztyn, 10-561 Olsztyn, Poland.
⁶ Department of Clinical Laboratory Diagnostics, Medical University of Białystok, Waszyngtona 15A, 15-269 Bialystok, Poland.

Abstract

Antibody levels that confer full protection against SARS-CoV-2 infection after the administration of different vaccine brands as well as the factors influencing the humoral immune response have been analyzed extensively ever since the vaccination program was launched in late 2020. The aim of this study was to determine anti-SARS-CoV-2S antibody titers in 100 healthcare workers 10 months after the administration of two BNT162b2 vaccine doses, and to investigate the influence of demographic characteristics, the presence of comorbidities and history of COVID-19 infection. The results were compared with antibody levels that were determined eight months after the administration of two BNT162b2 vaccine doses in our previous study. Antibody levels in venous blood serum were measured by the ECLIA method with the use of the Roche Cobas e411 analyzer. In all tested subjects, antibody titers remained high 10 months after vaccination, particularly in recovered COVID-19 patients, and only a minor decrease was observed relative to the values noted two months earlier.

Keywords: BNT162b2; COVID-19; anti-SARS-CoV-2 antibodies; healthcare workers.

Grants and funding

This research was funded by Roche Diagnostics, Hospital of the Ministry of the Interior and Administration in Olsztyn, University of Warmia and Mazury in Olsztyn.